Legal Status of Tadalafil (Cialis) in Ireland
The remaining 1,080 cases were
| Side Effect | Percentage of Users Reporting | Severity | Likelihood if Overused | Recommendations |
|---|---|---|---|---|
| Headache | 20% | Mild | Higher | Take with water |
| Muscle Pain | 10% | Mild to Moderate | Less likely | Monitor dosage |
| Flushing | 15% | Mild | Same | Avoid hot environments |
| Indigestion | 8% | Mild | Less likely | Take with food |
included in the analysis (Figure 1).
other ED treatments
Case information includes originating country and receipt date of the report, patient age and sex, tradename, active ingredient and indication of the suspect medicinal product(s), concomitant drugs, MedDRA PTs of reported ADRs, as well as ADR onset date, seriousness and outcomes (Appendix 1). Case narratives or information on patient medical history, comorbidities, reporter causality assessments or the mode of dispensing are not available. The FAERS Public Dashboard is updated on a quarterly basis. At the time of data retrieval for this analysis, data were current through 31 March, 2024. SMARS is a publicly available query tool cialis 5 miligramos of New Zealand’s national pharmacovigilance database (Appendix 5).
Comparison with existing literature
SMARS provides limited case level information on serious and non-serious ICSRs reported from New Zealand, including receipt date, patient age and sex, active ingredient of suspect and concomitant medicine(s) and the MedDRA PTs of reported ADRs (Appendix 1). Case narratives or information on drug indications, mode of dispensing, ADR seriousness or outcomes, patient medical history or comorbidities or reporter causality assessments are not available. Reports from other countries are not included. SMARS is updated on a monthly basis. At the time of data retrieval for this analysis, data were current through 01 May 2024.
WIPO Domain Name Decision D2005-0482 for great-cialis-viagra.biz (18 KB)
Sanofi Consumer Healthcare’s (CHC) pharmacovigilance database holds full case information for all ICSRs reported for Sanofi medicinal products from worldwide sources. ICSRs concerning sildenafil are not systematically collected in this database because Sanofi does not hold any marketing authorizations for sildenafil products. Currently, UK is the only country where Sanofi is marketing authorization holder and has launched a tadalafil product. In accordance with applicable regulatory requirements, ICSRs are entered into this database not only if they concern a Sanofi CHC product, but also if a Sanofi CHC product cannot be ruled out based on the reported information. Therefore, cases potentially concerning non-Sanofi CHC or not belonging to nonprescription tadalafil products might be stored in this database.